Metabolic tricks of cancer cells

Hönigová, Kateřina; Navrátil, Jiří; Peltanová, Barbora; Polanská, Hana; Raudenská, Martina; Masařík, Michal

doi:10.1016/j.bbcan.2022.188705

Cited by 48 publications

(38 citation statements)

References 323 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMD's anticancer activity is enhanced when combined with BGD [ 10 , 11 , 13 , 14 ]. In cancer cells, anaerobic glycolysis is the primary route [ 15 ]. Consequently, acidic circumstances boost betaglucosidase activity, which results in increased hydrocyanic acid and benzaldehyde formation and a deadly impact on cancer cells [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations

Alwan

Afshari

2022

BioMed Research International

View full text Add to dashboard Cite

Cancer of the prostate is an indicated type that is often recorded as a kind of cancer in men and the second critical cause of mortality through cancer cases. Many pharmacological investigations have shown that numerous herbal substances possess anticancer action. Amygdalin (AMD) has antitumour capabilities and works as an antioxidant, antibacterial, anti-inflammatory, and immune-regulating characteristics. The anticancer effects of amygdalin and its metabolizing enzymes, rhodanese (RHD) and betaglucosidase (BGD), were examined in vivo, as well as their antitumour processes. Novel, effective combination agents are necessary to increase existing cancer treatment rates. This research was aimed at determining the anticarcinogenic impact of amygdalin (AMD) in vivo. This research was aimed at determining the RHD and BGD on the anticarcinogenic impact of AMD in vivo. Subcutaneously, PC3 prostate cancer cell lines were implanted into nude mice. Mice were treated every day with 0.5 ml of 50 mg/ml (AMD), AMD+ (RHD 0.1 mg/ml), AMD+(BGD 0.1 mg/ml), and doxorubicin (DOX 50 mg/ml). Mice were normalized for negative control with untreated mice. In in vivo, morphopathological alterations in the tumour tissue were analyzed by histopathological staining methods. After 35 days of therapy, tumour growth and size inhibition were evident, indicating a function for the metabolic enzymes BGD and RHD in regulating AMD’s anticancer effect in vivo. We concluded the critical role of metabolic enzymes BGD and RHD in elevating the antigrowth of PC3 cancer cell lines in Balb/c nude mice treated with AMD.

show abstract

Section: Introductionmentioning

confidence: 99%

In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations

Alwan

Afshari

2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…To facilitate the antioxidant defense, multiple signaling pathways are involved in tumor cells in their metabolism, such as redox control alterations [ 3 , 10 ]. For example, the well-known PI3K/AKT axis upregulates Glc transport, glycolysis and lipogenesis in tumor cells.…”

Section: Carbohydrate Metabolic Reprogramming and Adaptation And Dire...mentioning

confidence: 99%

“…Similar results have also been found from the two double KO cells in the LDHA/LDHB genes that completely block glycolytic pathways, but leave a low growth inhibitory effect in tumor cells [ 6 ], indicating cancer cell’s metabolic plasticity. Glycolysis-reprogramming blockers for tumor metabolic pathways have been developed at the GPI [ 10 ] or LDHA/B inhibitors [ 32 ].…”

Section: Gpi Inhibition In Cancer Cellsmentioning

confidence: 99%

Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells

Abekura

Kim

Chang

et al. 2022

IJMS

View full text Add to dashboard Cite

Aerobic glycolysis is an emerging hallmark of many human cancers, as cancer cells are defined as a “metabolically abnormal system”. Carbohydrates are metabolically reprogrammed by its metabolizing and catabolizing enzymes in such abnormal cancer cells. Normal cells acquire their energy from oxidative phosphorylation, while cancer cells acquire their energy from oxidative glycolysis, known as the “Warburg effect”. Energy–metabolic differences are easily found in the growth, invasion, immune escape and anti-tumor drug resistance of cancer cells. The glycolysis pathway is carried out in multiple enzymatic steps and yields two pyruvate molecules from one glucose (Glc) molecule by orchestral reaction of enzymes. Uncontrolled glycolysis or abnormally activated glycolysis is easily observed in the metabolism of cancer cells with enhanced levels of glycolytic proteins and enzymatic activities. In the “Warburg effect”, tumor cells utilize energy supplied from lactic acid-based fermentative glycolysis operated by glycolysis-specific enzymes of hexokinase (HK), keto-HK-A, Glc-6-phosphate isomerase, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, phosphofructokinase (PFK), phosphor-Glc isomerase (PGI), fructose-bisphosphate aldolase, phosphoglycerate (PG) kinase (PGK)1, triose phosphate isomerase, PG mutase (PGAM), glyceraldehyde-3-phosphate dehydrogenase, enolase, pyruvate kinase isozyme type M2 (PKM2), pyruvate dehydrogenase (PDH), PDH kinase and lactate dehydrogenase. They are related to glycolytic flux. The key enzymes involved in glycolysis are directly linked to oncogenesis and drug resistance. Among the metabolic enzymes, PKM2, PGK1, HK, keto-HK-A and nucleoside diphosphate kinase also have protein kinase activities. Because glycolysis-generated energy is not enough, the cancer cell-favored glycolysis to produce low ATP level seems to be non-efficient for cancer growth and self-protection. Thus, the Warburg effect is still an attractive phenomenon to understand the metabolic glycolysis favored in cancer. If the basic properties of the Warburg effect, including genetic mutations and signaling shifts are considered, anti-cancer therapeutic targets can be raised. Specific therapeutics targeting metabolic enzymes in aerobic glycolysis and hypoxic microenvironments have been developed to kill tumor cells. The present review deals with the tumor-specific Warburg effect with the revisited viewpoint of recent progress.

show abstract

“…However, it is glycolysis rather than OXPHOS by which cancer cells predominantly tend to obtain energy even in the presence of abundant oxygen. This is a famous phenomenon known as “Warburg effect” in cancer ( Honigova et al, 2022 ). Although glycolysis is less efficient than OXPHOS with regard to the production of adenosine triphosphate (ATP), it results in a high abundance of additional metabolites which are beneficial to the highly proliferating cancer cells.…”

Section: Applications Of Metabolomics For Medicinal Plants In Gastroi...mentioning

confidence: 99%

Medicinal Plants for the Treatment of Gastrointestinal Cancers From the Metabolomics Perspective

et al. 2022

View full text Add to dashboard Cite

Gastrointestinal cancer (GIC), primarily including colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, and esophageal cancer, is one of the most common causes of cancer-related deaths with increasing prevalence and poor prognosis. Medicinal plants have been shown to be a great resource for the treatment of GIC. Due to their complex manifestations of multi-component and multi-target, the underlying mechanisms how they function against GIC remain to be completely deciphered. Cell metabolism is of primary importance in the initialization and development of GIC, which is reported to be a potential target. As an essential supplement to the newest “omics” sciences, metabolomics focuses on the systematic study of the small exogenous and endogenous metabolites involved in extensive biochemical metabolic pathways of living system. In good agreement with the systemic perspective of medicinal plants, metabolomics offers a new insight into the efficacy assessment and action mechanism investigation of medicinal plants as adjuvant therapeutics for GIC therapy. In this review, the metabolomics investigations on metabolism-targeting therapies for GIC in the recent 10 years were systematically reviewed from five aspects of carbohydrate, lipid, amino acid, and nucleotide metabolisms, as well as other altered metabolisms (microbial metabolism, inflammation, and oxidation), with particular attention to the potential of active compounds, extracts, and formulae from medicinal plants. Meanwhile, the current perspectives and future challenges of metabolism-targeting therapies of medicinal plants for GIC were also discussed. In conclusion, the understanding of the action mechanisms of medicinal plants in GIC from the metabolomics perspective will contribute to the clinical application of potential candidates from the resourceful medicinal plants as novel and efficient adjuvant therapeutics for GIC therapy.

show abstract

Metabolic tricks of cancer cells

Cited by 48 publications

References 323 publications

In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations

In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations

Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells

Medicinal Plants for the Treatment of Gastrointestinal Cancers From the Metabolomics Perspective

Contact Info

Product

Resources

About